CD8A and neoplasm: Whereas N803 in combination with vaccine promoted circulating activated CD8+ T cells with augmented expression of the trafficking chemokine receptor CXCR3, CD8+ T cells showed poor tumor infiltration and granzyme B expression in the TME, resulting in modest antitumor efficacy.